ABSTRACT

Background: Although secukinumab and ixekizumab both act by inhibiting IL-17A, some scientific evidence suggests that there are differences in efficacy between the two agents.

Objective: The aim of this study was to compare the short- and long-term effectiveness of ixekizumab and secukinumab in clinical practice.

Methods: A retrospective study was conducted on a cohort of 245 psoriatic patients receiving secukinumab or ixekizumab during the period from September 2016 to December 2019. The proportion of patients achieving PASI75, PASI90, and PASI100 at weeks 12 and 24 was calculated. We recorded the 12- and 24-month drug survival as a measure to assess long-term effectiveness.

Results: A higher proportion of patients in the secukinumab group achieved PASI75, 90, and 100 at 12 weeks. The Kaplan-Meier survival curve for any reason of discontinuation showed no differences between the two groups. Instead, the multivariate analysis for ineffectiveness, adjusted for potential confounders, showed a lower drug survival rate in the secukinumab group, with an adjusted HR of 2.57 (95% CI 1.05–6.28, p 0.038).

Conclusion: This real-life study demonstrated that ixekizumab and secukinumab are both highly effective in short- and long-term treatment of psoriasis, even though few differences exist concerning speed of action and long-term effectiveness.

摘要

背景：虽然苏金单抗和伊奇珠单抗都通过抑制 IL-17A 起作用，但一些科学证据表明这两种药物的疗效存在差异。

目的：本研究的目的是比较 ixekizumab 和苏金单抗在临床实践中的短期和长期有效性。

方法：对 245 名在 2016 年 9 月至 2019 年 12 月期间接受苏金单抗或依克珠单抗治疗的银屑病患者进行回顾性研究。计算第 12 周和 24 周达到 PASI75、PASI90 和 PASI100 的患者比例。我们记录了 12 个月和 24 个月的药物存活率，作为评估长期有效性的衡量标准。

结果：苏金单抗组中更高比例的患者在 12 周时达到 PASI75、90 和 100。因任何原因停药的 Kaplan-Meier 生存曲线显示两组之间没有差异。相反，针对潜在混杂因素调整后的无效多变量分析显示苏金单抗组的药物存活率较低，调整后的 HR 为 2.57（95% CI 1.05–6.28，p = 0.038）。

结论：这项现实生活中的研究表明，ixekizumab 和苏金单抗在银屑病的短期和长期治疗中都非常有效，尽管在作用速度和长期有效性方面几乎没有差异。